{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.8","upperLimit":"9.1","value":"2.1"},{"groupId":"OG001","lowerLimit":"1.8","upperLimit":"12.5","value":"7.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"description":"Determine the median progression-free survival. Progression-free survival is defined as the duration of time from study entry to time of progression or death or the date of last contact, whichever occurs first. Progression is defined by RECIST v1.1 criteria and is defined as an increase of at least 20% in the sum of the largest diameters of target lesions and/or the appearance of new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"This cohort will enroll patients with mesothelioma, uveal melanoma, renal cell carcinoma (clear cell type), and cholangiocarcinoma.\n\nNiraparib: Patients will take 300 mg of niraparib orally once daily each day of a 28 day cycle.","id":"OG000","title":"Cohort A"},{"description":"This cohort will enroll patients whose tumors have a known DNA damage response mutation in any of the following genes: ARID1A, ATM, ATR, BACH1 (BRIP1), BAP1, BARD1, BLM, CHEK1, CHEK2, CDK2, CDK4, ERCC, FAM175A, FEN1, IDH1, IDH2, MRE11A, NBN (NBS1), PALB2, POLD1, PRKDC (DNA-PK) PTEN, RAD50, RAD51, RAD52, RAD54, RPA1, SLX4, WRN, or XRCC. This cohort is open to patients with any type of malignancy (except prostate).\n\nNiraparib: Patients will take 300 mg of niraparib orally once daily each day of a 28 day cycle.","id":"OG001","title":"Cohort B"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"8 months","title":"Progression-Free Survival","type":"SECONDARY","unitOfMeasure":"months"}